#survodutide

2 stories

Clinical Trials April 8, 2026 · View digest

GLP-1 Therapies Rewriting Rules of Metabolic Disease at APhA 2026

The FLOW trial showed semaglutide reduced major kidney events by 24%, and retatrutide demonstrated up to 28.7% weight loss in TRIUMPH-4. The full pipeline including CagriSema, MariTide, and survodutide was presented.

Regulatory March 25, 2026 · View digest

FDA Grants Survodutide Breakthrough Therapy Designation for MASH

The FDA granted breakthrough therapy designation to survodutide, a dual glucagon/GLP-1 receptor agonist by Boehringer Ingelheim, for treating adults with MASH.